Anti-TREM-1 Antibody Selection for Noninvasive IBD Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are limited in efficacy and often have adverse side effects, and diagnostic methods are invasive, necessitating the development of safer and more effective therapeutic and diagnostic options.
Innovation Solution
The use of antagonistic anti-TREM-1 antibodies targeting specific TREM-1 associated genes to treat IBD, identified by measuring increased gene expression levels, and administering a therapeutically effective dose to reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (anti-inflammatory agents, immunosuppressants, antibiotics) are used for IBD, then disease symptoms are reduced, but treatment efficacy is limited and adverse side effects occur
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of TREM-1 receptor activation in IBD. By identifying TREM-1 as a key driver of inflammation and isolating it as a specific therapeutic target, the invention develops antibodies that selectively block this pathway, achieving better efficacy with reduced off-target side effects compared to broad-spectrum immunosuppressants
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific immunosuppression to specific TREM-1 pathway modulation. By measuring TREM-1 gene expression levels and administering targeted antibodies based on these measurements, the treatment achieves precise parameter control, improving efficacy while minimizing adverse effects through selective intervention
2Measurement precision
If invasive diagnostic methods (colonoscopy, tissue biopsies) are used for IBD diagnosis, then diagnostic accuracy is achieved, but patient invasiveness and discomfort increase
Solution Approach 1:
The patent introduces TREM-1 gene expression measurement as an intermediary diagnostic tool. Instead of directly visualizing intestinal tissue through invasive colonoscopy, the method uses blood or stool samples to measure TREM-1 expression levels, which serve as a mediator indicating disease presence and severity, thereby maintaining diagnostic accuracy while eliminating procedural invasiveness
Solution Approach 2:
The patent replaces the mechanical invasive diagnostic system (colonoscopy with physical insertion and tissue sampling) with a molecular measurement system. By substituting physical mechanical diagnosis with biochemical detection of TREM-1 expression in accessible samples, the invention achieves the same diagnostic information without mechanical intrusion into the patient's body
Data Source
AI summary
Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.